Buprenorphine for opiate addiction: potential economic impact.
about
A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disordersNew methods of treatment efficacy research: bridging clinical research and clinical practice.Practical considerations for the clinical use of buprenorphine.The impact of dispensing fees on compliance with opioid substitution therapy: a mixed methods study.Bridging the gap: a hybrid model to link efficacy and effectiveness research in substance abuse treatmentThe adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clustersBudgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain.Process improvement needs in substance abuse treatment: admissions walk-through results.Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence.Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients.Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program.Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013.Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting.Effects of Pharmacotherapies for Opioid Dependence on Participants' Criminal Behaviour and Expenditure on Illicit Drugs: An Australian National Evaluation (NEPOD)
P2860
Q27000732-1B770C54-EAFE-4123-87CC-8F06F9A138D3Q33669425-69AB2BAA-FECF-4109-ABBF-B4F1DC334C25Q33774853-294EC62F-9305-4902-89BA-0E743180EF2FQ34059799-04CBFB80-1F3B-4017-A38D-408779338EFAQ35074748-A6B96F36-A8B5-4805-B30F-B7D2A267AE8BQ35792939-8C5FE002-B921-4AC5-9D42-B836BA4189C0Q36110773-FC29B0E0-63AF-4EED-AE82-B896159A0E6DQ36296632-BFCD7F31-02D1-4BC1-8709-403DD81C769CQ36508384-A6DD2B46-A871-4433-AF62-8D4E491C9C84Q36750914-6DAF8B49-6AB0-454A-B61C-E3D922486843Q37105100-BF2EC995-3045-4C63-95F4-7FD1126C32AAQ41367554-B202B757-298E-4420-8A7A-F8A89240DFDBQ43584958-BA4FA723-D7D2-49EA-B012-C54D0EF004B7Q44336891-9576E09B-484D-49D8-8F7B-87DF4A38364CQ59287060-D9D09901-456A-4A89-BC40-5DBE5159153D
P2860
Buprenorphine for opiate addiction: potential economic impact.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Buprenorphine for opiate addiction: potential economic impact.
@ast
Buprenorphine for opiate addiction: potential economic impact.
@en
Buprenorphine for opiate addiction: potential economic impact.
@nl
type
label
Buprenorphine for opiate addiction: potential economic impact.
@ast
Buprenorphine for opiate addiction: potential economic impact.
@en
Buprenorphine for opiate addiction: potential economic impact.
@nl
prefLabel
Buprenorphine for opiate addiction: potential economic impact.
@ast
Buprenorphine for opiate addiction: potential economic impact.
@en
Buprenorphine for opiate addiction: potential economic impact.
@nl
P1476
Buprenorphine for opiate addiction: potential economic impact.
@en
P2093
P304
P356
10.1016/S0376-8716(00)00214-3
P577
2001-08-01T00:00:00Z